OraSure Announces $40 Million Stock Repurchase Program

Core Viewpoint - OraSure Technologies, Inc. has authorized a stock repurchase program of up to $40 million over the next twenty-four months, to be funded from cash on hand [1][2]. Company Overview - OraSure Technologies, Inc. is a leader in point-of-need and home diagnostic tests and sample management solutions, aiming to improve access, quality, and value of healthcare through innovative testing and sample management [3]. - The company, along with its subsidiaries DNA Genotek Inc. and Sherlock Biosciences, Inc., develops, manufactures, and distributes rapid diagnostic tests and sample collection devices globally [3]. Stock Repurchase Program - The stock repurchase may be executed through various methods in compliance with applicable laws, with the timing and amount determined at the management's discretion [2]. - The repurchase program can be modified, suspended, or discontinued at any time without prior notice [2].